Immune Thrombocytopenic Purpura – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder that leads to a decrease in platelet production, thus increasing the risk of bleeding. Current therapies for ITP can be broadly divided into immunomodulators and thrombopoietin receptor agonists (TPO–RAs). Systemic glucocorticoids and TPO–RAs are the cornerstones of clinical management; however, biologics such as rituximab provide additional options for refractory patients. In 2018, two novel therapies for chronic ITP—Rigel Pharmaceuticals’ Tavalisse (fostamatinib), an oral Syk inhibitor; and Sobi’s Doptelet (avatrombopag), a second-generation TPO–RA—launched in the United States. This report offers insights from real-world claims data into prescribing trends in ITP to help new players better understand current treatment practices in ITP that may help define the market niche for their emerging product.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed ITP patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed ITP patients?
- How have TPO–RAs been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of ITP patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of ITP patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States.
Key companies: Amgen, Novartis, Rigel Pharmaceuticals, Sobi.
Key drugs: Antibiotics, avatrombopag (Doptelet), eltrombopag (Promacta), fostamatinib (Tavalisse), rituximab (Rituxan, biosimilars), romiplostim (Nplate), systemic glucocorticoids.
Solution enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.
Table of contents
- Immune Thrombocytopenic Purpura - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
- Treatment Algorithms CDA Immune Thrombocytopenic Purpura US May 2023
- Treatment Algorithms CDA Immune Thrombocytopenic Purpura 2023 Dashboard
Bethany A. Kiernan, Ph.D., Director, Healthcare Research & Data Analytics, Infectious, Niche, and Rare Diseases. Dr. Kiernan manages and supports a team of analysts and managers producing both syndicated and custom market research analyses in a range of niche / rare indications as well as infectious diseases. Dr. Kiernan has extensive experience in market forecasting and broad knowledge across a range of CNS disorders, rare diseases, and infectious diseases. Her previous experience includes eight years of scientific research conducted at Tufts University School of Medicine, Case Western Reserve University, and the College of the Holy Cross. She earned her doctorate in neurosciences from Case Western Reserve University.